ISTPOOL: Detection of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction (PCR) After Pooling Pharyngeal, Anorectal and Urinary Samples

Sponsor
Centre Hospitalier Régional d'Orléans (Other)
Overall Status
Completed
CT.gov ID
NCT03568695
Collaborator
(none)
166
5
1
23.6
33.2
1.4

Study Details

Study Description

Brief Summary

This study aims to compare the sensitivity of detecting Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium by real-time multiplex PCR in a pooled analysis (i.e. gathering pharyngeal, anorectal and urinary samples) versus the standard of care (where a real-time multiplex PCR is made in each of the three samples).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Two samples on each of the three sites (pharynx, rectum, urine)
N/A

Detailed Description

Patients detected positive for one of the three (Sexually Transmitted Infection)STIs (Chlamydia trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium) on one site will be re-sampled twice at each of the three sites (pharynx, rectum, urine) before receiving antibiotics. Then, a real-time multiplex PCR will be performed on the pooled sample (merging pharyngeal, anorectal and urinary samples) versus on each of the three samples separately (i.e. standard of care) to compare both sensitivities.

Study Design

Study Type:
Interventional
Actual Enrollment :
166 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Detection of Chlamydia Trachomatis, Neisseria Gonorrhoeae and Mycoplasma Genitalium by Real-time Multiplex Polymerase Chain Reaction After Pooling Pharyngeal, Anorectal and Urinary Samples, in Men Who Have Sex With Men
Actual Study Start Date :
Jun 29, 2018
Actual Primary Completion Date :
Jun 16, 2020
Actual Study Completion Date :
Jun 16, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: Detected patients

If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .

Diagnostic Test: Two samples on each of the three sites (pharynx, rectum, urine)
two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .

Outcome Measures

Primary Outcome Measures

  1. To evaluate the sensitivity of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium detection in a pooled analysis [Day 1]

    Sensitivity rates will be compared using non parametric statistical analysis. The pooling method will be considered as acceptable if the sensitivity reach at least 95%.

Secondary Outcome Measures

  1. Impact of the strategies on the costs [Day 1]

    Costs will include time of lab staff, DNA extraction, PCR material in the two strategies and related to 1000 patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient having provided a written consent;

  • Patient age > 18 years;

  • Man who have sex with men tested positive for one the three STIs : Chlamydia trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium

  • Covered by health insurance

Exclusion Criteria:
  • Being under tutorship

  • Being deprived of liberty

  • Patient who received antibiotic treatment prior to study inclusion and re-sampling

Contacts and Locations

Locations

Site City State Country Postal Code
1 CH de Niort Niort France 79021
2 CHR d'Orleans Orléans France 45067
3 CHU de Poitiers Poitiers France 86000
4 CH Laennec Quimper France 29107
5 CHU de Tours Tours France 37044

Sponsors and Collaborators

  • Centre Hospitalier Régional d'Orléans

Investigators

  • Principal Investigator: Thierry PRAZUCK, Dr, CHR d'Orléans

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Centre Hospitalier Régional d'Orléans
ClinicalTrials.gov Identifier:
NCT03568695
Other Study ID Numbers:
  • CHRO-2018-01
First Posted:
Jun 26, 2018
Last Update Posted:
Sep 1, 2020
Last Verified:
Aug 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Régional d'Orléans
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2020